Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2012.

Trading has been in line with management's expectations, with turnover of approximately £22.0 million in the six months ended 30 June 2012. HydromolTM continues to perform well, with growth of 28% over the first half of 2011.

As announced on 22 June 2012, Sanofi Pasteur has temporarily suspended manufacturing of ImmuCystTM with supply estimated to resume in late 2013.

Alliance continues to explore a number of acquisition opportunities, some of which are at a very advanced stage.

The Company's interim results for the six months ended 30 June 2012 are scheduled to be released on 12 September 2012.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.